ADVM · As filed with the SEC
Adverum Biotechnologies cash flow statement, by fiscal year
The statement as Adverum Biotechnologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD thousands
| USD thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | (130,927) | (117,165) | (154,536) | (145,540) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization | 3,653 | 5,644 | 6,528 | 4,645 |
| Stock-based compensation expense | 14,350 | 17,569 | 20,079 | 25,194 |
| Net accretion of discount on marketable securities | (1,907) | (1,935) | (880) | 2,770 |
| Accreted interest on BPI | — | — | — | 0 |
| Non-cash lease expense | 7,495 | 13,027 | — | — |
| Non-cash sublease loss/(income) | 14,000 | — | — | — |
| Loss on disposal of property and equipment | 2 | 50 | 122 | — |
| Impairment of long-lived assets | — | 224 | 2,124 | 1,063 |
| Foreign currency remeasurement loss | — | — | — | 0 |
| Other | (39) | 1 | (1,417) | (25) |
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other current assets | 638 | 298 | 1,653 | (2,257) |
| Deposit and other long-term assets and deferred rent receivable | — | 182 | (394) | (990) |
| Operating lease right-of-use assets | — | — | 4,040 | 2,719 |
| Deposit and other long-term assets | (68) | — | — | — |
| Accounts payable | (262) | (369) | 845 | (1,612) |
| Accrued expenses and other liabilities | 3,021 | (5,206) | 64 | 3,274 |
| Other non-current liabilities | — | — | 74 | 0 |
| Lease liability | (2,418) | (3,222) | 13,607 | 2,928 |
| Net cash used in operating activities | (92,462) | (90,902) | (108,091) | (107,831) |
| Cash flows from investing activities: | ||||
| Purchases of marketable securities | (101,901) | (36,718) | (104,363) | (407,514) |
| Maturities of marketable securities | 60,400 | 134,401 | 257,899 | 492,356 |
| Sales of marketable securities | — | — | 0 | 8,990 |
| Purchases of property and equipment | (388) | (808) | (11,816) | (15,123) |
| Net cash (used in) provided by investing activities | (41,889) | 96,875 | 141,720 | 78,709 |
| Cash flows from financing activities: | ||||
| Proceeds from offering of common stock, net of issuance costs | — | — | 0 | 1,685 |
| Proceeds from issuance of common stock and pre-funded warrants in private placement, net of issuance costs | 119,361 | — | — | — |
| Payment of deferred offering costs | 0 | (420) | — | — |
| Proceeds from issuance of common stock pursuant to option exercises | 146 | 1 | 3 | 51 |
| Taxes paid related to net share settlement of restricted stock units | — | — | — | 0 |
| Proceeds from employee stock purchase plan | 496 | 488 | 604 | 901 |
| Repayment of BPI loan | — | — | 0 | (240) |
| Net cash provided by financing activities | 120,003 | 69 | 607 | 2,397 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (14,348) | 6,042 | 34,236 | (26,725) |
| Cash and cash equivalents and restricted cash at beginning of period | — | — | 36,698 | 63,423 |
| Cash and cash equivalents and restricted cash at end of period | — | — | — | 36,698 |
| Cash, cash equivalents and restricted cash at beginning of period | 76,976 | 70,934 | 36,698 | — |
| Cash, cash equivalents and restricted cash at end of period | 62,628 | 76,976 | 70,934 | — |
| Supplemental schedule of noncash information | ||||
| Right-of-use assets obtained in exchange for lease liability | — | — | 0 | 84,005 |
| Decrease in right-of-use asset and lease liability due to termination | — | — | 0 | 15,768 |
| Remeasurement of right-of-use asset on lease modification | — | — | 2,842 | 2,052 |
| Remeasurement of operating lease right-of-use assets and liabilities | 0 | 13,711 | — | — |
| Fixed assets in accounts payable and current liabilities | 201 | 91 | 64 | 1,402 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.